AstraZeneca (NYSE: AZN) reported Q2 EPS of $0.83, $0.07 better than the analyst estimate of $0.76. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.56 billion.

The Growth Platforms grew by 7% in the half. Of the six platforms, the performance included:

• Emerging Markets: +7%. Encouraging China growth of 11%
• Diabetes: +18%. A good performance underpinned by the success of Farxiga
• Respiratory: +1%. Strong Emerging Markets sales of Symbicort, pricing compression in the US and Europe
• New Oncology: Sales of $251m reflected the successful ongoing launch of Tagrisso

For earnings history and earnings-related data on AstraZeneca (AZN) click here.